What is HC Wainwright’s Forecast for BCYC Q1 Earnings?

Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) – Investment analysts at HC Wainwright issued their Q1 2026 earnings estimates for Bicycle Therapeutics in a report issued on Friday, October 31st. HC Wainwright analyst S. Ramakanth expects that the company will post earnings of ($1.06) per share for the quarter. The consensus estimate for Bicycle Therapeutics’ current full-year earnings is ($3.06) per share. HC Wainwright also issued estimates for Bicycle Therapeutics’ Q2 2026 earnings at ($1.08) EPS, Q3 2026 earnings at ($1.10) EPS and Q4 2026 earnings at ($1.14) EPS.

BCYC has been the topic of several other reports. Morgan Stanley reduced their target price on Bicycle Therapeutics from $17.00 to $13.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 12th. Citigroup restated an “outperform” rating on shares of Bicycle Therapeutics in a research report on Friday. Citizens Jmp increased their price target on Bicycle Therapeutics from $10.00 to $12.00 and gave the stock a “market outperform” rating in a report on Friday, October 31st. JMP Securities set a $12.00 target price on shares of Bicycle Therapeutics in a research note on Friday. Finally, Royal Bank Of Canada reissued a “sector perform” rating and set a $11.00 target price (down from $27.00) on shares of Bicycle Therapeutics in a research note on Friday. Seven research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Bicycle Therapeutics has an average rating of “Moderate Buy” and an average price target of $19.80.

Bicycle Therapeutics Price Performance

Shares of BCYC stock opened at $6.87 on Monday. The business’s 50 day simple moving average is $7.66 and its 200 day simple moving average is $7.87. Bicycle Therapeutics has a one year low of $6.10 and a one year high of $25.39. The stock has a market capitalization of $476.16 million, a PE ratio of -1.90 and a beta of 1.48.

Bicycle Therapeutics (NASDAQ:BCYC) last released its quarterly earnings results on Friday, August 8th. The company reported ($1.14) EPS for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.19). Bicycle Therapeutics had a negative net margin of 884.51% and a negative return on equity of 36.05%. The company had revenue of $2.90 million during the quarter, compared to the consensus estimate of $9.43 million.

Insider Buying and Selling at Bicycle Therapeutics

In other Bicycle Therapeutics news, CEO Kevin Lee sold 3,231 shares of the firm’s stock in a transaction on Friday, October 3rd. The shares were sold at an average price of $8.41, for a total value of $27,172.71. Following the transaction, the chief executive officer directly owned 475,310 shares of the company’s stock, valued at approximately $3,997,357.10. This trade represents a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold 8,527 shares of company stock valued at $71,738 over the last 90 days. 8.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Bicycle Therapeutics

Several large investors have recently added to or reduced their stakes in the business. Principal Financial Group Inc. lifted its position in Bicycle Therapeutics by 64.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,148,402 shares of the company’s stock valued at $8,889,000 after acquiring an additional 451,135 shares in the last quarter. Vanguard Personalized Indexing Management LLC bought a new position in shares of Bicycle Therapeutics in the third quarter valued at approximately $100,000. State of Tennessee Department of Treasury bought a new position in shares of Bicycle Therapeutics in the second quarter valued at approximately $100,000. Soleus Capital Management L.P. bought a new position in Bicycle Therapeutics during the 2nd quarter valued at $695,000. Finally, Monimus Capital Management LP bought a new position in Bicycle Therapeutics during the 2nd quarter valued at $592,000. Institutional investors own 86.15% of the company’s stock.

About Bicycle Therapeutics

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.